Olaparib, the first-in-class PARP-inhibitor, was approved for the treatment of platinum-sensitive and BRCA-mutated types of ovarian cancer in the US and the EU in 2014, followed by numerous trials applying Olaparib or other PARP inhibitors as single agents or in combination therapies [10]. This evidence concerns the gene PARP1 and ovarian cancer.